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Antihistamines inhibit histamine signaling by blocking histamine H1 receptor (H1R) or suppressing H1R
signaling as inverse agonists. The H1R gene is upregulated in patients with pollinosis, and its expression
level is correlated with the severity of nasal symptoms. Here, we show that antihistamine suppressed
upregulation of histidine decarboxylase (HDC) mRNA expression in patients with pollinosis, and its
expression level was correlated with that of H1R mRNA. Certain antihistamines, including mepyramine
and diphenhydramine, suppress toluene-2,4-diisocyanate (TDI)-induced upregulation of HDC gene
expression and increase HDC activity in TDI-sensitized rats. However, d-chlorpheniramine did not
demonstrate any effect. The potencies of antihistamine suppressive effects on HDC mRNA elevation were
different from their H1R receptor binding afﬁnities. In TDI-sensitized rats, the potencies of antihistamine
inhibitory effects on sneezing in the early phase were related to H1R binding. In contrast, the potencies of
their inhibitory effects on sneezing in the late phase were correlated with those of suppressive effects on
HDC mRNA elevation. Data suggest that in addition to the antihistaminic and inverse agonistic activities,
certain antihistamines possess additional properties unrelated to receptor binding and alleviate nasal
symptoms in the late phase by inhibiting synthesis and release of histamine by suppressing HDC gene
transcription.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Pollinosis, a seasonal allergic rhinitis, affects approximately 30%
of the Japanese population (1). Histamine plays important roles in
the pathogenesis of allergic rhinitis; its action is mainly mediated
through the histamine H1 receptor (H1R). Antihistamines act as
inverse agonists to inhibit histamine signaling by blocking H1R or
suppressing H1R signaling (2,3). Therefore, antihistamines are
employed as ﬁrst-line treatment for the nasal symptoms of
pollinosis.
H1R gene expression strongly correlates with the severity of
allergic symptoms in toluene-2,4-diisocyanate (TDI)-sensitized rats
and patients with pollinosis (4,5). Further, the suppression of
upregulated H1R gene expression alleviates nasal symptoms (6e9).
Allergic reactions are characterized further by disrupting the Tnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Table 1
Nucleotide sequences of primers and probes.
Primer/probe name Sequence
Human HDC mRNA
Sense primer 50-CCTGAATGCAGCTCTCAATGTG-30
Anti-sense primer 50-CAGAGTCCCTGAAGTATATCCTCAGAC-30
Probe FAM-TTGCCCTCTGCAGGCCATGGTTTA-TAMRA
Rat HDC mRNA
Sense primer 50-GCAGCAAGGAAGAACAAAATCC-30
Anti-sense primer 50-CAACAAGACGAGCGTTCAGAGA-30
Probe FAM-AAAGCGCATGAGCCCAATGCTGAT-TAMRA
Mouse HDC mRNA
Sense primer 50-TCTACCTCCGACATGCCAACT-30
Anti-sense primer 50-CCACAGCTTAATGGAGCGAAAG-30
Probe FAM-CACGGACTTCATGCATTGGCAGATCC-TAMRA
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Th2 proﬁle (10). Th2 cytokine genes, including interleukin (IL)-4
and IL-5 genes, are upregulated in TDI-sensitized rats and patients
with pollinosis; their expression levels were correlated with that of
H1R gene (4,7,11), suggesting crosstalk between the H1R and Th2
cytokine signaling pathways. Intranasal application of IL-4 and
histamine increases H1R gene and IL-4 gene expression, respec-
tively (7). These ﬁndings suggest that H1R signaling is important for
pollinosis development and that drugs designed to suppress H1R
signaling will be effective for treating allergies.
Because histidine decarboxylase (HDC) is the only enzyme that
catalyzes histamine synthesis, HDC gene expression is an impor-
tant regulatory step in histamine signaling (12). Histamine is
released from subcutaneous mast cells during the anaphylaxis
phase via an IgE-mediated mechanism, whereas in the post-
anaphylaxis phase, histamine is produced because of an
increased HDC activity (13). HDC mRNA levels increase in patients
with allergic rhinitis and bronchial asthma (14). Application of TDI
upregulates HDC mRNA expression and HDC enzymatic activity
and histamine content in the nasal mucosa (7). Moreover, sup-
pression of HDC gene expression alleviates the nasal symptoms of
TDI-sensitized rats.
Here we show that preseasonal prophylactic treatment with
antihistamines suppressed the upregulation of HDC mRNA
expression in patients with pollinosis and that the expression level
of HDC mRNA was strongly correlated with that of H1R mRNA.
Because insufﬁcient data are available on the effect of antihista-
mines on HDC gene expression, we used TDI-sensitized rats to
investigate the effects of antihistamines on nasal symptoms, his-
tamine levels in nasal discharges, HDC activity, and HDC gene
expression in the nasal mucosa. Our data suggest that during the
late-phase response, mepyramine and diphenhydramine signiﬁ-
cantly suppressed TDI-induced upregulation of HDC mRNA, HDC
activity, and histamine content in the nasal mucosa with potencies
that differed from their Ki values for [3H]mepyramine binding af-
ﬁnity to H1R.
2. Materials and methods
2.1. Analysis of HDC mRNA expression in the nasal mucosa of
patients with pollinosis
We determined HDC mRNA levels using the remaining nasal
mucosa samples of patients previously analyzed for H1R mRNA
levels (5). Patient information, preparations for scraping the nasal
mucosa, evaluation of nasal symptoms, and other experimental
conditions were previously described (5). Among 25 patients with
allergic rhinitis caused by Japanese cedar pollen, 8 patients (3
males and 5 females; mean age, 47.9 years) who were treated at
the Department of Otolaryngology, Yashima General Hospital
before the peak pollen period (February 20eMarch 26, 2009)
were administered prophylactic treatment with antihistamines
(ebastine, 10 mg/day p.o., n ¼ 5; and fexofenadine, 120 mg/day
p.o., n ¼ 3). The treatment lasted for 17.9 ± 11.0 days (mean ± SD)
before the follow-up visit during the peak pollen period when
nasal symptoms were evaluated and nasal mucosa scrapings were
obtained from patients by an otolaryngologist as previously
described (5).
Sneezing, watery rhinorrhea, and nasal obstruction were sepa-
rately scored on a 0e5 point scale before nasal sampling. Under
local anesthesia using 4% lidocaine, the surface of each patient's
inferior nasal conchawas scratched with a small spatula to obtain a
sample of the nasal mucosa. Of the initial 25 patients, the
remaining patients (8 males and 9 females; mean age, 46.3 years)
who ﬁrst visited the hospital during the peak pollen period but didnot take antihistamines or any other treatment were designated as
the no treatment group.
Total RNA isolated using the RNAqueous Micro Kit (Applied
Biosystems, Foster City, CA) was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). The sequences of the HDC primers and TaqMan probe
are listed in Table 1. The pumilio RNA binding family member 1
(PUM1) primer and probe kit (Hs 00206469-m1, Applied Bio-
systems) was used to generate a standard (5). The data are
expressed as the ratio of HDC mRNA to PUM1 mRNA as previ-
ously described. The ethics committee of Tokushima University
Hospital and Yashima General Hospital approved this study;
written informed consent was obtained from each patient before
the study commenced.
2.2. Animal studies
Six-week-old male Brown Norway rats (200e250 g, Japan SLC,
Hamamatsu, Japan) with free access to water were kept in a room
maintained at constant temperature (25 ± 2 C) and humidity
(55% ± 10%) with 12-h light/dark cycle. TDI-sensitization was per-
formed as previously reported (12). Antihistamines were orally
administered once daily for 3 weeks. The number of sneezes was
measured during the 10-min period just after (early phase reaction)
or 9 h (late phase reaction) after TDI provocation. The antihista-
mines (10 mg/kg each) were orally administered 1 h before TDI
provocation, whereas the control group received water. All exper-
imental procedures were performed in accordance with the
guidelines of the Animal Research Committee of Tokushima
University.
2.3. Real-time quantitative reverse transcription polymerase chain
reaction
Rat nasal mucosa samples collected using RNAlater (Applied
Biosystems, Foster City, CA, USA) 4 h after provocation were ho-
mogenized using a Polytron (Model PT-K; Kinematica AG, Littau/
Luzern, Switzerland) in 10 volumes of ice-cold TRIzol; total RNA
was prepared as previously described (7). RNA samples (8 mg) were
reverse-transcribed using SuperScript II reverse transcriptase
(Invitrogen); real-time PCR was conducted as previously described
(7). TaqMan primers and probes were designed using Primer Ex-
press software (Applied Biosystems). The primers used to detect rat
HDC mRNA are listed in Table 1. To standardize the starting mate-
rial, Rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Control Reagents (VICProbe; Applied Biosystems) were used. Data
are expressed as the ratio of HDC mRNA to GAPDH mRNA.
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nasal mucosa
Nasal mucosawas removed from the nasal septum 9 h after TDI-
provocation and homogenized with 10 volumes of ice-cold HDC
buffer containing 0.1 M potassium phosphate buffer, pH 6.8,
0.2 mM DTT, 0.01 mM pyridoxal 50-phosphate, 1% polyethylene
glycol (approximately 300 kDa), and 100 mg/ml PMSF. The ho-
mogenates were centrifuged at 10,000  g for 15 min at 4 C, and
one-half of the supernatant (supernatant A) was dialyzed thrice
against HDC buffer for 6 h at 4 C (supernatant B). Histamine
content in supernatant A was determined using high-performance
liquid chromatography (12). The HDC activity of supernatant B was
determined by incubation for 4 h at 37 C in 0.25 mM L-histidine.
HDC activities were calculated according to histamine levels (minus
the blank). Protein concentrations were determined using the
bicinchoninic acid protein assay reagent (Sigma) and bovine serum
albumin as standard.
2.5. Determination of histamine content in nasal-cavity lavage ﬂuid
Nasal lavage was performed 9 h after TDI provocation using a
slight modiﬁcation of a published method (15). Rats were anes-
thetized with diethyl ether and then polyethylene tubing con-
nected to a regulated vacuum device positioned in the left nostril;
slight negative pressure was then applied. Washing with 1.5 ml PBS
(37 C) was performed from the right to left nostrils and repeated in
reverse order. Nasal exudates were transferred to a new tube; 10 ml
perchloric acid (60% w/v) was added, The suspension was centri-
fuged at 10,000  g for 15 min at 4 C, transferred to another tube
and stored at20 C. The histamine content in the supernatant was
determined as described above.
2.6. Effect of antihistamines on PMA-induced upregulation of HDC
gene expression in RAW 264.7 cells
RAW 264.7 cells were cultured in Eagle's minimal essential
medium containing 10% fetal calf serum and 1% anti-
bioticeantimycotic (Invitrogen) at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2. RAW 264.7 cells (70% conﬂuence) in 6-
well dishes were treated with 10 mM antihistamines 1 h before
the addition of 100 nM of phorbol 12-myristate 13-acetate (PMA).
After 5 h, the cells were harvested using 700 ml RNAiso Plus (Takara)
to isolate total RNA that was reverse transcribed (5 mg) using a High
Capacity cDNA Reverse Transcription kit (Applied Biosystems).
Real-time PCR was performed as described above.
2.7. Statistical analysis
The results are shown as mean ± SEM, and the data acquired
using nasal mucosa of patients with pollinosis are shown as
mean ± SD. Statistical analyses were performed using the unpaired
t test or one-way ANOVA using Dunnett's test with GraphPad Prism
software (GraphPad Software, Inc. San Diego CA). Correlations were
analyzed using the Spearman rank correlation method. Values of
p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Effect of preseasonal prophylactic treatment with antihistamine
on HDC mRNA expression in the nasal mucosa of patients with
pollinosis
Preseasonal prophylactic treatment with antihistamines signif-
icantly suppressed HDC mRNA expression (Fig. 1A). HDC mRNAexpression levels were positively correlated with nasal symptoms
(Fig. 1B) and H1R expression levels (Fig. 1C).
3.2. Effect of antihistamines on TDI-induced upregulation of HDC
gene expression, HDC activity, histamine content in the nasal
mucosa, and histamine levels in nasal lavage ﬂuid of TDI-sensitized
rats
Compared with controls, HDC mRNA expression in TDI-
sensitized rats was signiﬁcantly increased after provocation with
TDI. Mepyramine and diphenhydramine strongly suppressed TDI-
induced upregulation of HDC gene expression in TDI-sensitized
rats (Fig. 2A). The other antihistamines, except d-chlorphenir-
amine, tended to suppress the TDI-induced increase in HDC mRNA
levels. We next measured HDC activity in the nasal mucosa of TDI-
sensitized rats 9 h after TDI provocation. TDI application for 3
weeks induced a signiﬁcant increase in HDC activity (Fig. 2B).
Pretreatment with mepyramine and diphenhydramine signiﬁ-
cantly suppressed the TDI-induced increase in HDC activity. Aze-
lastine, epinastine, and olopatadine tended to suppress HDC
activity. In contrast, d-chlorpheniramine, which did not suppress
TDI-induced HDC upregulation, failed to suppress HDC activity.
Provocation with TDI induced a signiﬁcant increase in histamine
content in the nasal mucosa of TDI-sensitized rats (Fig. 3). Pre-
treatment with mepyramine and diphenhydramine signiﬁcantly
decreased histamine content in the nasal mucosa. Azelastine, epi-
nastine, and olopatadine tended to reduce the histamine level in
the nasal mucosa. d-Chlorpheniramine had no detectable effect.
Analysis of nasal lavage samples revealed a notable increase in
histamine content 9 h after TDI provocation, which was signiﬁ-
cantly suppressed by mepyramine and olopatadine. Azelastine
tended to decrease histamine content, whereas d-chlorphenir-
amine did not have a detectable effect (Fig. 4).
3.3. Effect of antihistamines on TDI-induced nasal symptoms of
TDI-sensitized rats
To determine whether histamine induced an allergic reaction,
we monitored sneezing just after or 9 h after provocation. Pre-
treatment with antihistamines reduced the number of TDI-induced
sneezes at both times (Fig. 5). The potencies of inhibitory effects of
the antihistamines on the number of sneezes just after provocation
with TDI were similar to their respective afﬁnities of binding to H1R
(Table 2) (16e19). In contrast, 9 h after TDI provocation, these ef-
fects were similar to the inhibition of HDC mRNA expression.
3.4. Effect of antihistamines on PMA-induced upregulation of HDC
gene expression in RAW 264.7 cells
PMA treatment upregulates HDC mRNA expression in RAW
264.7 cells by activating the PKC/ERK signaling pathway (20). When
RAW 264.7 cells were pretreated with mepyramine and azelastine,
the upregulation of HDCmRNA expression induced by PMAwas not
suppressed, although it was signiﬁcantly suppressed by d-chlor-
pheniramine (Fig. 6).
4. Discussion
In the present study, we demonstrate that certain antihista-
mines, including mepyramine and diphenhydramine, alleviate
allergic symptoms through their antihistaminic effects and by
suppressing histamine synthesis by inhibiting HDC mRNA expres-
sion. H1R gene expression was highly correlated with the severity
of allergic symptoms, and compounds that suppress H1R gene
expression alleviate the symptoms of allergy of patients with
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Fig. 1. Effect of preseasonal prophylactic treatment with antihistamines on the upregulation of HDC mRNA (A) and the relationship between the expression levels of HDC mRNA and
the nasal symptoms (B) and the expression level of H1R mRNA (C). The scraping of the nasal mucosa from the patients with Japanese cedar pollinosis were collected and total RNA
was isolated using the RNAqueous Micro Kit. HDC mRNA was determined by quantitative real-time RT-PCR. Data for the sum of sneezing and watery rhinorrhea scores and the
expression of H1R mRNAwere obtained fromMizuguchi et al. (8). In A, Data are expressed as means ± SD. For statistical analysis, unpaired t-test was used. *P < 0.05 vs. no treatment
group. In B and C, ﬁlled circles and open squares represent data obtained from patients with or without preseasonal prophylactic treatment with antihistamines, respectively.
Correlation was analyzed by Spearman's rank correlation test.
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Fig. 2. Antihistamines block TDI-induced upregulation of HDC mRNA (A) and suppress HDC activity (B). In A, HDC mRNAwas determined by quantitative real-time RT-PCR 4 h after
provocation. In B, HDC activity in the nasal mucosa was measured by HPLC 9 h after provocation. Data are expressed as means ± SEM. Control, vehicle control; TDI, TDI-provoked
rats without administration of antihistamines (TDI-control); Diphen, diphenhydramine; Mepy, mepyramine; Diphen, diphenhydramine; Prom, promethazine; Azlas, azelastine;
Epinas; epinastine; Olop, olopatadine; Chlor, d-chlorpheniramine. **P < 0.01, and *P < 0.05 vs. TDI; yyP < 0.01 and yP < 0.05 vs. d-chlorpheniramine (n ¼ 4).
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pathogenesis of allergic inﬂammation (10). For example, in patients
with pollinosis, histamine inﬂuences the expression and actions of
Th2 cytokines through crosstalk between the H1R and Th2 cytokine
signaling pathways; and Th2 cytokines, in turn, modulate the
production and release of histamine (21,22).
We demonstrated that prophylactic treatment with antihista-
mines suppressed TDI-induced upregulation of H1R and IL-4 mRNA
expressions in TDI-sensitized rats (4). We also showed that direct
administration of IL-4 into the nasal cavities of normal non-TDI-
treated rats upregulated H1R mRNA expression (7). Intranasal
histamine application increased IL-4 mRNA levels in normal rats
(7), and H1R expression level was strongly correlated with that of
IL-5 in patients with pollinosis (11). These ﬁndings suggest that
H1R gene expression is correlated with that of Th2-cytokine genes
and that suppression of H1R gene expression affects the expression
levels of Th2 cytokines. Therefore, we consider that the suppression
of H1R signaling is important for treating allergies.
In the present study, we used TDI-sensitized rats as a model of
allergic rhinitis. Allergic rhinitis is deﬁned as an IgE-mediateddisease (1). In contrast, rhinitis caused by TDI is a non-IgE medi-
ated disease (23). For example, TDI-speciﬁc IgE is not detected in
mice exposed to TDI, although total IgE and TDI-speciﬁc IgG titers
are elevated (24). Therefore, nasal symptoms and pathogenesis
observed in TDI-sensitized rats may differ from those of antigen-
induced IgE-dependent rhinitis. However, intranasal application
of TDI induces nasal symptoms, including sneezing, and watery
rhinorrhea in TDI-sensitized guinea pigs (25), which are similar to
those observed in patients with allergic rhinitis. TDI-sensitized rats
display many characteristic features of human allergic rhinitis (e.g.,
nasal symptoms), including inﬁltration of eosinophils and mast
cells (26), increased levels of cytokines (27e30), elevation of H1R
mRNA and protein expression (31), increased levels of HDC mRNA,
HDC activity, and histamine content (12). Accordingly, dis-
tinguishing between immunological sensitization and irritation by
TDI is difﬁcult, probably because that the underlying mechanisms
driving TDI-induced rhinitis share similarities with allergic rhinitis
caused by ubiquitous airborne protein allergens. Therefore, we
consider that TDI-sensitized rats can serve as a model for human
allergic rhinitis.
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model rats. Nasal discharge from both vestibules was collected by polyethylene tubing
connected to a regulated vacuum 9 h after provocation. Histamine content was
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regulation of HDC expression is considered to be important. Pre-
seasonal prophylactic treatmentwith antihistamine suppressed the
upregulation of HDC mRNA expression in patients with pollinosis
(Fig. 1). Further, HDC mRNA expression level was strongly corre-
lated with that of H1R mRNA. These ﬁndings suggest that the
suppression of HDC expression decreases histamine-induced H1R
mRNA expression level and alleviates nasal symptoms, supporting
our hypothesis that the regulation of HDC expression is important
for treating allergies. The importance of histamine in allergies is
also demonstrated by the results of studies using HDC-deﬁcient
mice (33,34).Sensitization and provocation with TDI elevates HDC mRNA
levels in the nasal mucosa, followed by increases in HDC activity
and histamine content (12). Here pretreatment with antihista-
mines, except d-chlorpheniramine, suppressed TDI-induced HDC
mRNA upregulation at different levels, which indicates the exis-
tence of novel targets and mechanisms of antihistaminic action as
well as inverse agonistic activities. The potencies of the inhibitory
effects of antihistamines on the increase in HDC mRNA levels were
different from their binding afﬁnities for the H1R (16e19), sug-
gesting that this effect is unrelated to H1R binding. Moreover, hu-
man nasal mucosal epithelial and vascular endothelial cells express
H1R (35). The results are consistent with our unpublished immu-
nohistochemical analysis of TDI-sensitized rats. To our knowledge,
there are no reports of HDC expression in epithelial and endothelial
cells; thus, it is unlikely that these cells produce histamine in an
autocrine manner. These ﬁndings support our hypothesis that the
suppressive effect of antihistamines on the HDC-induced elevation
of mRNA expression is not related to H1R-binding.
Antihistamines have pharmacological properties unrelated to
receptor binding (36). Azatadine, d-chlorpheniramine, mepyr-
amine, and promethazine reduce the release of proinﬂammatory
mediators frommast cells and basophils, chemotaxis and activation
of inﬂammatory cells, particularly eosinophils, and expression of
adhesion molecules in epithelial cell lines induced by immuno-
logical or nonimmunological stimuli (37). Desloratadine inhibits
IgE-mediated IL-4 and IL-13 secretion from human basophils (38),
and antihistamines suppress Th2 response (3,7e9,12,39). However,
no reports demonstrate that antihistamines suppress HDC ex-
pressions. To the best of our knowledge, the present study reports
the ﬁrst evidence demonstrating that antihistamines suppress the
upregulation of HDC mRNA expression.
Although several studies demonstrate the upregulation of HDC
mRNA expression, the mechanism is unknown. Because PMA
upregulates HDC gene expression (40), PKC signaling may induce
the upregulation of HDC gene transcription. For example, the PKC/
ERK/CEBPb pathway mediates PMA-induced upregulation of HDC
mRNA expression in RAW 264.7 cells (20). Our present data
demonstrated that mepyramine and azelastine did not inhibit
PMA-induced upregulation of HDC gene expression in RAW
264.7 cells, although they suppressed HDC gene expression in TDI-
sensitized rats. In contrast, d-chlorpheniramine did not suppress
HDC expression in TDI-sensitized rats, although it inhibited PMA-
induced HDC upregulation in RAW 264.7 cells. Therefore, it is un-
likely that PKC signaling upregulates HDC mRNA expression
induced by TDI. NF-kB represents another candidate because its
expression is elevated in patients with allergic rhinitis (41). Dexa-
methasone signiﬁcantly reduces the upregulation of HDC mRNA
expression in TDI-sensitized rats (12), and the glucocorticoid
receptoredexamethasone complex binds to AP-1 or NF-kB and
suppresses their transcriptional activities. Therefore, the suppres-
sive effect of dexamethasone on TDI-induced HDC mRNA upregu-
lation may be explained by the inhibition of NF-kB signaling.
However, we have no data to prove this, and there are no reports of
NF-kB-induced HDC gene expression.
It was reported that the expression of HDC gene was transcrip-
tionally regulated by DNAmethylation at the region including the GC
box sequence in the promoter (42). Demethylation of this GC box by
the treatment with 5-azacytidine induced a high level of HDC mRNA
expression, suggesting that HDC expression levels were positively
correlated with hypomethylation of the HDC promoter region (43). It
was also reported that Sp-1 binds to the GC box in the HDC promoter
and protects from de novo methylation (42). Since long-term effect
was observed in TDI-sensitized rats, DNA methylation status or Sp-1
dependent transcription may be affected by antihistamines such as
mepyramine and diphenhydramine. Investigation of the effect of
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Fig. 5. Pretreatment with antihistamines reduced the number of sneezes in nasal allergy model rats. The number of sneezes was counted for 10 min just after provocation (A) and
9 h after provocation (B). Data are expressed as means ± SEM. Control, vehicle control; TDI, TDI-control; Diphen, diphenhydramine; Mepy, mepyramine; Azlas, azelastine; Epinas,
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or Sp-1-dependent HDC gene transcription is under way in our
laboratory.
The novel mechanism of the regulation of HDC gene expression
described here is not uniform among antihistamines. For example,
we showed that mepyramine and diphenhydramine signiﬁcantly
suppressed HDC activity and histamine content in the nasal mucosa
of TDI-sensitized rats, whereas they were also suppressed by aze-
lastine, epinastine, and olopatadine, although the effects of the
latter were not statistically signiﬁcant. In contrast, d-chlorphenir-
amine had no detectable effect. The potencies of the inhibitory
effects of antihistamines were different from their binding afﬁnities
for the H1R. Because mepyramine, diphenhydramine, epinastine,
and d-chlorpheniramine are inverse agonists and olopatadine is a
neutral antagonist (3), it is unlikely that the ability to suppress HDC
mRNA expression was correlated with inverse agonistic activity.
The diversity among antihistamines in the suppression of HDC
mRNA expression is of interest because uncovering their structur-
eeactivity relationships may facilitate the discovery of new drugs
for treating allergies. When we investigated the levels of histamine
in the nasal discharges, similar results were obtained. For example,
mepyramine and olopatadine signiﬁcantly suppressed the TDI-
induced release of histamine. The ability of olopatadine to inhibit
histamine release was not related to the suppression of HDC mRNA
expression but related to its function as a membrane stabilizer (44).
Here the inhibitory effect of azelastine was not statistically signif-
icant, and d-chlorpheniramine did not affect histamine release.Table 2
Ki values of antihistamines used in this study determined by [3H]mepyramine
displacement assay.
Antihistamines Ki (nM)
Mepyramine 1.7a, 4.5b
d-Chlorpheniramine 7.5a, 8.0b
Diphenhydramine 17b
Promethazine 2.9b
Azelastine 7.0c
Epinastine 3.8c
Olopatadine 41d
Data were taken from:
a Ref. (16).
b Ref. (17).
c Ref. (18).
d Ref. (19).To assess the clinical signiﬁcance of these results, we measured
the number of sneezes for 10 min just after and 9 h after provo-
cation. Each antihistamine signiﬁcantly suppressed sneezing at
both times, and the potency of suppression in the early phase was
similar to receptor-binding afﬁnity. In contrast, in the late phase,
the suppressive potency might be correlated with histamine syn-
thesis, suggesting that certain antihistamines suppressed the nasal
symptom by inhibiting histamine synthesis through the suppres-
sion of HDC mRNA expression.
In conclusion, we demonstrate here that the long-term effects of
certain antihistamines are mediated through inhibition of HDC
gene expression and down-regulation of the H1R signaling
pathway. These ﬁndings provide a new perspective on the long-
term effects of antihistamines on allergies. Speciﬁcally, mepyr-
amine and diphenhydramine inhibited allergic responses during
the late phase. Therefore, detailed knowledge on the mechanism
that regulates HDC gene expression may be helpful for the devel-
opment of new drugs for treating allergies.0
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Fig. 6. Effect of antihistamines on PMA-induced upregulation of HDC gene expression
in RAW 264.7 cells. RAW 264.7 cells were treated with 10 mM of antihistamine 1 h
before stimulation with 100 nM PMA. After a 5-h treatment with PMA, total RNA was
isolated, and the HDC mRNA levels were determined by real-time quantitative RT-PCR.
Data are presented as the means ± SEM. (n ¼ 4). *P < 0.05 vs. PMA.
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